A0A8C9I693 (A0A8C9I693_9PRIM) Piliocolobus tephrosceles (Ugandan red Colobus)
mitogen-activated protein kinase kinase UniProtKBInterProInteractive Modelling
419 aa; Sequence (Fasta) ;
6 identical sequences: Homo sapiens: O14733; Pongo abelii: A0A2J8RD71; Pan troglodytes: K7CKG2, A0A803KLG6; Gorilla gorilla gorilla: G3R9J9; Macaca mulatta: H9EQH1
Available Structures
36 Experimental Structures
Description | PDB ID | Oligo-state | Range | Ligands | ||
---|---|---|---|---|---|---|
Crystal structure of JNK1 bound to a MKK7 docking motif |
Heteromer O14733; P45983; | 1×ANP; 4×SO4; | ||||
Assess | ||||||
Crystal structure of MKK7 (MAP2K7) in an active state, allosterically triggered by the N-terminal h… | monomer | 1×NA; 17×EDO; | ||||
Assess | ||||||
MAP2K7 mutant -C218S | monomer | 4×GOL; | ||||
Assess | ||||||
MAP2K7 C218S mutant-inhibitor | monomer | 1×95U; | ||||
Assess | ||||||
Crystal structure of MKK7 (MAP2K7), apo form | monomer | |||||
Assess | ||||||
Crystal structure of MKK7 (MAP2K7) with ibrutinib bound at allosteric site | monomer | 9×EDO; 4×DMS; 1×1E8; | ||||
Assess | ||||||
Crystal structure of MKK7 (MAP2K7) in complex with ibrutnib, with covalent and allosteric binding m… | monomer | 8×EDO; 4×DMS; 1×1E8; 1×8E8; | ||||
Assess | ||||||
Crystal structure of MKK7 (MAP2K7) in complex with ASC69 | monomer | 1×IHH; | ||||
Assess | ||||||
Crystal structure of MKK7 (MAP2K7) covalently bound with type-II inhibitor SB1-G-23 | monomer | 3×EDO; 1×OQ2; | ||||
Assess | ||||||
Protein kinase MKK7 in complex with difluoro-phenethyltriazole-substituted pyrazolopyrimidine | monomer | 1×24N; | ||||
Assess | ||||||
Protein kinase MKK7 in complex with phenethyltriazole-substituted pyrazolopyrimidine | monomer | 1×2GI; | ||||
Assess | ||||||
Crystal structure of S287D,T291D MKK7 (MAP2K7), apo form | monomer | |||||
Assess | ||||||
Crystal structure of MKK7 (MAP2K7) covalently bound with type-II inhibitor TL10-105 | monomer | 1×EDO; 1×OQ8; | ||||
Assess | ||||||
Structure of the mitogen activated kinase kinase 7 active conformation | monomer | |||||
Assess | ||||||
MAP2K7 C276S mutant-inhibitor | monomer | 1×95U; 1×EPE; | ||||
Assess | ||||||
Structure of the mitogen activated kinase kinase 7 dfg-out conformation | monomer | |||||
Assess | ||||||
Protein kinase MKK7 in complex with methoxycyclohexyl-substituted indazole | monomer | 1×1XZ; | ||||
Assess | ||||||
Protein kinase MKK7 in complex with tolyl-substituted indazole | monomer | 1×2I8; | ||||
Assess | ||||||
Protein kinase MKK7 in complex with cyclobutyl-substituted indazole | monomer | 1×21I; | ||||
Assess | ||||||
Protein kinase MKK7 in complex with 5-bromo-2-hydroxyphenyl-substituted pyrazolopyrimidine | monomer | 1×GOL; 1×2I5; | ||||
Assess | ||||||
Crystal structure of MAP2K7 complexed with a covalent inhibitor 12 | monomer | 1×FU6; 1×GOL; | ||||
Assess | ||||||
The structure of MKK7 in complex with the covalent 4-amino-pyrazolopyrimidine 4a | monomer | 1×862; | ||||
Assess | ||||||
Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine 1k | monomer | 1×6HL; | ||||
Assess | ||||||
A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7 | monomer | 2×EPE; 1×GOL; | ||||
Assess | ||||||
Crystal structure of human mitogen-activated protein kinase kinase 7 activated mutant (S287D, T291D) | monomer | |||||
Assess | ||||||
The structure of MKK7 in complex with the covalent 4-amino-pyrazolopyrimidine 3a | monomer | 1×H8Z; 1×PG4; | ||||
Assess | ||||||
Crystal structure of the C276S mutant of MAP2K7 | monomer | |||||
Assess | ||||||
Crystal structure of MKK7 (MAP2K7) in complex with K00007 | monomer | 6×EDO; 1×SU9; | ||||
Assess | ||||||
Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidin 1b | monomer | 1×J0B; | ||||
Assess | ||||||
THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-oxozeaenol | monomer | 1×1FM; | ||||
Assess | ||||||
Crystal structure of MKK7 (MAP2K7) covalently bound with CPT1-70-1 | monomer | 9×EDO; 1×6HF; | ||||
Assess | ||||||
A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7 | monomer | |||||
Assess | ||||||
A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7 | monomer | |||||
Assess | ||||||
Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine inhibitor 1h | monomer | 1×J0E; | ||||
Assess | ||||||
Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine 1m | monomer | 1×J3N; | ||||
Assess | ||||||
Dual specificity mitogen-activated protein kinase kinase 7 in complex with pyrazolopyrimidine 1a | monomer | 1×J3H; | ||||
Assess |
1 SWISS-MODEL model
Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
6yg1.1.A | monomer | 0.84 | 99.42 | |||
Assess |